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Abstract
Background: Bone and soft tissue sarcomas (BSTS) are rare malignant tumors. Recently, the combination of
gemcitabine and docetaxel (GD) was shown to have activity as second-line setting in BSTS. However, the efficacy as
first-line and adjuvant settings and precise profiles of adverse events in Japanese patients are not known yet. In the
present study, the feasibility and efficacy of GD in patients with BSTS were investigated.
Methods: Patients with BSTS treated with GD in our institutions were retrospectively analyzed. Information regarding
clinical features, adverse events, and outcome was collected and statistically studied. Factors related to survival were
analyzed using log-rank test and Cox proportional hazard regression method.
Results: A total of 134 patients were analyzed. GD was carried out as adjuvant setting in 9, first-line in 23, second-line
in 56, and third-or-greater line in 46 patients. The response rate (RR) for all patients was 9.7%. RR for the patients
treated as adjuvant or first-line setting was 18.8%, whereas that as second-or-greater line was 6.9%. The median
progression-free survival (PFS) and overall survival (OS) of all patients were 4.8 (95% CI 3.5–6.1) and 16.4 (95% CI 9.8–22.9)
months, respectively. Survival tended to be better in the patients treated as first-line than in those treated
as second-or-greater line. Multivariate analysis demonstrated that history of prior chemotherapy (p = 0.046)
and response to GD (p = 0.009) was significantly associated with PFS and OS, respectively. The leucopenia
and neutropenia were the most frequent adverse events, and grade 3 or 4 leucopenia and neutropenia
were observed in 69.4 and 72.4% of the patients. Grade 2 or 3 pneumonitis was observed in one (0.7%) and four
(3.0%) patients, respectively. All the patients with pneumonitis had experienced prior chemotherapy and/or
radiotherapy.
Conclusions: GD used as both first- and second/later line is effective chemotherapy for a proportion of patients with
advanced BSTS. Higher response rate and better outcome was achieved in chemotherapy-naïve patients. This regimen
is associated with high incidence of severe hematological toxicity, as well as the risk of severe pneumonitis, especially
in pre-treated patients. GD is promising for further analysis by phase III study for the patients with BSTS.
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Background
Bone and soft tissue sarcomas (BSTS) are very rare ma-
lignant tumors. BSTS account for approximately 1% of
all malignancies. According to the Bone and Soft Tissue
Tumor Registry reported by the Musculoskeletal Tumor
Committee of the Japanese Orthopaedic Association,
only 591 cases of bone sarcoma (BS) and 1509 cases of
soft tissue sarcomas (STS) were registered in 2013 in
Japan [1, 2]. Because of the rareness of BSTS, it is diffi-
cult to develop novel treatments for the tumors. Current
standard chemotherapy for BSTS consists of old re-
agents such as doxorubicin (DOX) and ifosfamide (IFO)
[3, 4]. DOX has remained a key drug for many years in
the treatment of BSTS, and its response rate (RR) for
sarcomas is approximately 25%. IFO is another key drug
for BSTS with RR of approximately 30%. The combin-
ation of DOX with IFO has been shown to improve out-
comes of the patients with localized STS [5], whereas
the combination failed to show the improvement of
prognosis of the patients with advanced STS [6].
Gemcitabine (GEM) is a fluorine-substituted pyrimi-
dine analog, and is phosphorylated to the diphosphate
and triphosphate metabolites. These active metabolites
inhibit DNA synthesis and exhibit anti-tumor effects [7].
Docetaxel (DOC) has the activity to inhibit the
depolymerization of microtubular bundles to free
tubulin [8], resulting in the disruption of cell mitosis.
The RR of GEM and DOC alone for sarcomas was re-
ported to be approximately 3 and 0%, respectively, and
each drug was inactive as single agent for BSTS [9, 10].
Recent studies have demonstrated the efficacy of the
combination of GEM plus DOC (GD) [11–16]. GD regi-
men indicated the high response rates for the patients
with advanced uterine leiomyosarcomas in both first-line
[17] and second-line settings [18]. It has been also re-
ported that GD exhibited higher response rates,
progression-free survival (PFS), and overall survival (OS)
than single-agent GEM in a randomized phase II trial for
patients with advanced STS previously treated by up to
three prior regimens [19]. The efficacy of GD as the
second-line setting for advanced BSTS was also reported
in the prospective and retrospective studies [20, 21]. How-
ever, only one study has been reported showing the effects
of GD as adjuvant or first-line treatment on BSTS [22].
GD regimen is also known to be feasible and less toxic
than DOX+IFO regimen [11–18]. Although pulmonary
toxicity of both GEM and DOC should be noted, the
combination of GEM and DOC would not increase the
pulmonary toxicity [19]. On the other hand, it has been
demonstrated that pulmonary toxicities by GD were
severe among Japanese patients in a Japan Clinical
Oncology Group (JCOG) trial. The clinical trial,
JCOG0104, evaluated the efficacy of GD for non-small
cell lung cancer as second-line setting and resulted in
the early termination due to unexpected three
treatment-related deaths with interstitial pneumonitis
[23]. These observations suggest that the incidence of
pulmonary toxicity might be high in Japanese patients.
However, there is no study demonstrating the precise
profiles of the adverse events of GD including the
pulmonary toxicities in Japanese patients with BSTS.
In the present study, we analyzed the profiles of the
adverse events and efficacy of GD, including as adjuvant and
first-line settings, for 134 patients with BSTS treated in the
institutions participating in the Bone and Soft Tissue Tumor
Study Group (BSTTSG) of JCOG. This study is one of the
largest series of the patients with BSTS treated by GD [11].
Methods
We retrospectively reviewed the records of the institutions
of JCOG BSTTSG participating in the present study from
July 2002 to September 2014. A total of 134 patients
suffered from BSTS and treated by GD regimen in our
institutions participating in JCOG BSTTSG were enrolled
in the present study. This study was approved by the
Institutional Review Board at Oita University, and a
waiver of informed consent was provided.
The GD regimen consisted of GEM administrated in
day 1 and 8 and DOC administrated in day 8. Basically,
GEM was given intravenously in 30 min in 100 ml
saline, and DOC was given intravenously over 60 min in
250 ml saline with premedication of 16 mg/day of dexa-
methasone for 3 days. Patients were given therapeutic
and second-line prophylactic granulocyte colony stimu-
lating factor if they had grade 4 neutropenia or febrile
neutropenia. The median dose of GEM was 890 mg/m2/day
(range 490–1000 mg/m2/day) and that of DOC was
70 mg/m2 (range 42–100 mg/m2). The chemotherapy
was repeated until disease progression or intolerance to the
regimen. The indication of adjuvant chemotherapy for
BSTS was basically as follows: histologically high-grade
sarcomas, larger than 5 cm in maximum diameter without
metastasis, and deep-seated in tumor location. The median
number of cycles of GD was three (range 1–14 cycles) for
all patients. The mean follow-up period for 56 surviving
patients was 18 months (range 1–75 months), and that for
78 patients who died was 14 months (range 1–72 months).
Toxicity was evaluated according to the National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) version 3.0. The radio-
logical evaluation of the response to the chemotherapy
was assessed using Response Evaluation Criteria in Solid
Tumor (RECIST) ver. 1.1. The progression-free survival
(PFS) was defined as the time period from the day GD
started until the day of the first evidence of disease
progression or death. The overall survival (OS) was de-
fined as the time period from the day GD started until
the day of death or last follow-up. The PFS and OS were
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calculated using the Kaplan-Meier method. Differences
in survivals were assessed by the log-rank test and Cox
proportional hazard regression method. Differences were
considered significant when p values were <0.05. Statis-
tical analysis was done using IBM SPSS Statistics 22.0
software (IBM, Armonk, NY, USA).
Results
Patient characteristics
A total of 134 patients were analyzed in the present
study (Table 1). The median age of the patients was
53 years old (range 10–78 years old) at the treatment by
GD. The sites of primary lesions were soft tissues in 105
patients, and bones in 29 patients. The two most
frequent histologic tumor types of STS were leiomyosar-
coma (n = 33) and undifferentiated pleomorphic sarcoma
(n = 18). The histologic tumor types of BS were osteosar-
coma 15, Ewing sarcoma 3, leiomyosarcoma 5, undiffer-
entiated pleomorphic sarcoma of bone 2, and other 4.
Among 134 patients, the metastatic and/or locally
advanced BSTS were observed in 125 patients, and GD
was carried out as first-line setting in 23 patients,
second-line in 56 patients, and third-or-greater line in
46 patients. On the other hand, GD regimen was carried
out as adjuvant chemotherapy with resection of localize
primary tumor in 9 patients. The frequent chemotherapy
regimens prior to GD for the patients with advanced
BSTS were DOX+IFO (38 patients), DOX alone (21
patients), and IFO alone (18 patients). The median num-
ber of lines of prior chemotherapy was 1 (range 1–5 reg-
imens). The prior radiation therapy had been carried out
for 45 patients. Median dose of radiation was 56 Gy.
The median doses of GEM and DOC were 890 mg/m2/day
(range 490–1000 mg/m2/day) and 70 mg/m2 (range 42–
100 mg/m2) for the patients with advanced BSTS, and
900 mg/m2/day (range 550–900 mg/m2/day) and
70 mg/m2 (range 50–100 mg/m2) for the non-advanced
cases. The median number of cycles of GD was 3 (range
1–14 cycles) for the advanced cases, and 5 (range 2–9 cy-
cles) for the non-advanced cases treated as adjuvant
chemotherapy. The two most frequent reasons for the
discontinuation of GD regimen were progression of
disease (81%) and adverse events (10%).
Response and survival
The RECIST-assessed response rate was 9.7% (13/134) for
all patients. Two patients were assessed as complete re-
sponse (CR), 11 partial response (PR), 55 stable disease
(SD), 55 progressive disease (PD), and 11 not evaluable
(NE). The patients who had no prior chemotherapy, i.e.,
treated as adjuvant or first-line setting exhibited 1 CR and
5 PR, and RR was 18.8% (6/32). On the other hand, the
patients treated as second-or-greater line had 1 CR and 6
PR, resulting in RR of 6.9% (7/102). Although the
difference was not significant, RR of GD as adjuvant or
first-line setting chemotherapy tended to be better than
that for second-or-greater line setting chemotherapy. RR
for the patients with BS was only 3.4% (1PR/29), whereas
that for STS was 11.4% (2CR+10PR/105). Objective
response by histological subtypes of BSTS was summa-
rized in Table 2. The response (CR/PR) was observed in
the patients with leiomyosarcoma, undifferentiated pleo-
morphic sarcoma, malignant peripheral nerve sheath
tumor, angiosarcoma, and Ewing sarcoma. RR for leio-
myosarcoma and undifferentiated pleomorphic sarcoma
was 13.2% (5/38) and 15.0% (3/20), respectively (Table 2).
At the last follow-up time, 56 patients were alive and 78
patients were dead. The median PFS for all patients was
4.8 months (95% CI 3.5–6.1) (Fig. 1a). The median PFS
for the patients treated by GD as adjuvant therapy (n = 9)
was not reached yet (p < 0.001), and estimated 5-year PFS
was 70%. The median PFS as first-line (n = 23) was
6.7 months (95% CI 5.9–7.5), that as second-line (n = 56)
was 4.0 months (95% CI 2.5–5.6), and that as third-or-greater
line (n= 46) was 2.0 months (95% CI 0.2–3.9), respectively.
The median OS of all patients was 16.4 months (95% CI
9.8–22.9) (Fig. 1b). The median OS for the patients treated
by GD as adjuvant therapy was not reached yet (p = 0.004),
and estimated 5-year OS was 75%. The median OS as first-
line was 22.5 months (95% CI 7.4–37.6), that as second-line
was 14.1 months (95% CI 8.5–19.7), and that as third-or-
greater line was 9.3 months (95% CI 6.6–12.0), respectively.
Although the difference in OS between first-line and
second-or-greater line setting was not significant, survival
tended to be better in the patients treated as first-line set-
ting (Fig. 2).
Next, the effects of doses on GD were investigated.
The patients treated with GEM 900 mg/m2/day and
DOC 70 mg/m2 (G900/D70) (n = 18), which was the
same as the median dose, exhibited 1 CR and 2 PR, and
RR rate was 16.7%. The patients treated with doses
higher than G900/D70 (>G900/D70) (the mean dose of
GEM 939 mg/m2/day and DOC 89 mg/m2) (n = 32)
exhibited only 1 PR and RR was 3.1%. The median PFS
and OS of patients with G900/D70 were 7.2 months
(0.4–32.5 months) and 13.7 months (0.6–32.5 months),
respectively, whereas those with >G900/D70 were
3.3 months (0.3–54.6 months) and 6.3 months (1.6–
54.6 months), respectively.
Univariate analysis for the potential prognostic factors
for PFS in 134 patients was carried out (Table 3).
Histologic subtype (undifferentiated pleomorphic sar-
coma vs. leiomyosarcoma vs. others) and history of prior
chemotherapy (first-line setting vs. second-or-greater
line setting) were significantly correlated with PFS. Age,
the sites of primary lesions, bone or soft tissue tumors,
response to GD (CR or PR vs. SD or PD), and doses of
GD were not prognostic factors for PFS. Multivariate
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analysis also performed to demonstrate factors influen-
cing to PFS. History of prior chemotherapy (p = 0.046)
was a significant prognostic factor for PFS (Table 3).
On the other hand, histologic subtype (p = 0.002) and
response to GD (p = 0.010) were significant prognostic
factors for OS in univariate analysis (Table 4). Multi-
variate analysis demonstrated that response to GD
(p = 0.009) was significantly associated with OS
(Table 4). The patients with leiomyosarcoma and
UPS showed similar OS and PFS; however, the prog-
nosis of leiomyosarcoma patients was significantly
better than that of other histologic subtypes exclud-
ing UPS (for PFS, p = 0.004 and for OS, p = 0.001).
Adverse events
There was no treatment-related death. The leucopenia
and neutropenia were the most frequent adverse events
by GD for BSTS (Table 5). Grade 3 or 4 leucopenia and
neutropenia were observed in 93 (69.4%) and 97 (72.4%)
patients. Grade 3 or 4 anemia and thrombocytopenia
were observed in 25 (18.7%) and 37 (27.6%) patients.
Febrile neutropenia was observed in 13 out of 134
patients (9.7%). The most frequent non-hematological
toxicities were nausea and anorexia; however, these ad-
verse events were modest. Grade 3 nausea and anorexia
were observed only in two (1.5%) and one (0.7%)
Table 1 Patient characteristics (n = 134)
Age Median (years) 53
Range 10–78
Bone tumor 29 (21.6%)





Soft tissue tumor 105 (78.4%)
Primary site Head and neck 4 (3.0%)
Shoulder girdle 3 (2.2%)

























Ewing sarcoma 4 (3.0%)










DOX alone 21 (15.7%)
IFO alone 18 (13.4%)





Prior radiation 45 (33.6%)
Table 2 Response to GD by histological subtypes
CR PR SD PD NE RR (%)
All 2 11 55 55 11 9.7
Leiomyosarcoma 0 5 19 12 2 13.2
Undifferentiated
pleomorphic sarcoma
1 2 11 4 2 15.0
Osteosarcoma 0 0 7 8 2 0
Liposarcoma 0 0 2 5 2 0
Synovial sarcoma 0 0 3 4 0 0
Malignant peripheral
nerve sheath tumor
0 1 0 5 1 14.3
Angiosarcoma 0 1 1 1 1 25.0
Ewing sarcoma 0 1 1 2 0 25.0
Epithelioid sarcoma 0 0 1 3 0 0
Rhabdomyosarcoma 0 0 2 1 0 0
Others 1 1 8 10 1 9.5
CR complete response, PR partial response, SD stable disease, PD progressive
disease, NE not evaluable, RR response rate
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patients. Grade 4 non-hematological toxicity was found
only in one patient (0.7%) as infection. Regarding lung
toxicities, dyspnea and pneumonitis were observed in
nine patients (6.7%) as all grades. Grade 2 or 3 pneumon-
itis was observed in one (0.7%) and four (3.0%) patients,
respectively. All the five patients were assessed as intersti-
tial pneumonitis and successfully treated by steroid-pulse
therapy. All the patients with pneumonitis had experi-
enced previous chemotherapy. Four out of five patients
received GD as third-or-greater line and one as second-
line chemotherapy. Three out of five patients with grade 2
or 3 pneumonitis had been treated by prior radiotherapy,
and dose and site of radiation were 30 Gy to the chest
wall, 54 Gy to the lung, and 50 Gy to the thigh.
Among 32 patients treated by GD as adjuvant or first-
line therapy, grade 3 or 4 leucopenia and neutropenia
were observed in 17 (53.1%) and 21 (65.6%) patients
(Table 6). Grade 3 or 4 anemia and thrombocytopenia
were observed in five (15.6%) and three (9.4%) patients.
Grade 4 non-hematological toxicity was not observed.
Grade 3 nausea and anorexia were not observed,
whereas grade 3 dyspnea was observed in one patient
(3.1%). The pneumonitis was observed in two patients
(6.3%) only as grade 1.
For the patients treated as second-or-greater line
(n = 102), grade 3 or 4 leucopenia and neutropenia
were observed in both 76 patients (74.5%) (Table 7).
Grade 3 or 4 anemia and thrombocytopenia were
observed in 20 (19.6%) and 34 (33.3%) patients. The
lung toxicities were observed as dyspnea and pneumonitis
in eight (7.8%) and seven (6.9%) patients as all grades, re-
spectively. Grade 3 pneumonitis was observed in four
patients (3.9%). The incidence of grade 3 and 4 leucopenia
(HR 0.214, 95% CI 0.021–0.406, p = 0.022) and
thrombocytopenia (HR 0.24, 95% CI 0.103–0.376, p = 0.008)
of the patients treated as adjuvant or first-line setting
were significantly less frequent than those as second-
or-greater line setting.
Discussion
Recent studies have demonstrated that the combination
of GEM with DOC is effective for BSTS, and that GD
regimen is supposed to have milder toxicity than DOX
+IFO, the standard regimen for STS [11–16, 19]. In a
clinical trial JCOG0304, in which DOX+IFO was adminis-
trated for high-grade STS, the incidences of grade 3 and 4
leucopenia, neutropenia, anemia, thrombocytopenia, and
febrile neutropenia were 97.2, 98.6, 55.6, 15.3, and 18.2%,
respectively [24, 25]. It has been reported that the inci-
dences of grade 3 and 4 toxicities observed in GD were
Fig. 1 Kaplan-Meier estimates of survival of all patients. a Progression-free survival. b Overall survival
Fig. 2 Kaplan-Meier estimates of overall survival of the patients
treated with GD as adjuvant, first-line, second-line, and third-or-greater
line setting
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lower than those in DOX+IFO; leucopenia approxi-
mately 10–40%, neutropenia 10–70%, anemia 5–15%,
thrombocytopenia 10–40%, and febrile neutropenia
0–10% [11–16, 19]. In the present study, the inci-
dences of grade 3 and 4 adverse events by GD were
consistent with the previous studies. Grade 3 or 4
neutropenia, anemia, and febrile neutropenia were ob-
served in 72.4, 18.7, and 9.7%, respectively, of the patients
received GD. Furthermore, when GD was administrated
as adjuvant or first-line setting, the incidences of grade 3
or 4 leucopenia and thrombocytopenia were significantly
lower than those as second-or-greater setting.
On the other hand, GD regimen is also known to have
the risk of interstitial pneumonitis. In a randomized trial,
JCOG0104, which was conducted to confirm the super-
iority of GD on survival of the patients with previously
Table 3 Univariate and multivariate analyses for progression-free
survival
Univariate analysis
Factors HR (95% CI) p value
Age (years)
<50 (vs. ≥50) 1.23 (0.82–1.84) 0.322
Tumor origin
Bone (vs. soft tissue) 1.05 (0.65–1.69) 0.843
Primary site 0.648




Visceral (vs. extremities) 1.48 (0.78–2.83) 0.231
Histological subtype 0.008
UPS (vs. leiomyosarcoma) 1.20 (0.61–2.35) 0.591
Others (vs. leiomyosarcoma) 2.01 (1.23–3.21) 0.004
Prior chemotherapy 0.028





SD/PD (vs. CR/PR) 2.05 (0.99–4.23) 0.053
Multivariate analysis




















Table 4 Univariate and multivariate analyses for overall survival
Univariate analysis
Factors HR (95% CI) p value
Age (years)
<50 (vs. ≥50) 1.20 (0.76–1.89) 0.436
Tumor origin
Bone (vs. soft tissue) 1.32 (0.77–2.27) 0.318
Primary site 0.633
Trunk (vs. extremities) 0.85 (0.43–1.68) 0.639
Retroperitoneum (vs. extremities) 0.65 (0.31–1.37) 0.259
Visceral (vs. extremities) 1.15 (0.56–2.35) 0.702
Histological subtype 0.002
UPS (vs. leiomyosarcoma) 1.24 (0.55–2.81) 0.608
Others (vs. leiomyosarcoma) 2.54 (1.46–4.42) 0.001
Prior chemotherapy 0.126
Second-line (vs. first-line) 1.38 (0.72–2.65) 0.332
Third-or-greater line (vs. first-line) 1.90 (1.00–3.62) 0.052
Response to GD
SD/PD (vs. CR/PR) 3.81 (1.37–10.55) 0.010
Multivariate analysis














Third-or-greater line (vs. first-line)
Response to GD
SD/PD (vs. CR/PR) 3.99 (1.42–11.22) 0.009
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Table 5 Adverse events in all patients (n = 134)
Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 9 8 21 44 49 3 91.0 69.4
Neutrophils 9 7 17 30 67 4 90.3 72.4
Hemoglobin 27 41 38 23 2 3 77.6 18.7
Platelets 55 21 18 24 13 3 56.7 27.6
AST 87 38 3 3 0 3 32.8 2.2
ALT 82 35 9 5 0 3 36.6 3.7
Anorexia 52 59 15 2 0 6 56.7 1.5
Nausea 65 49 14 1 0 5 47.8 0.7
Vomiting 103 22 4 0 0 5 19.4 0.0
Diarrhea 112 13 2 2 0 5 12.7 1.5
Fatigue 50 59 15 6 0 4 59.7 4.5
Febrile neutropenia 120 0 0 13 0 1 9.7 9.7
Fever 97 22 12 1 0 2 26.1 0.7
Infection 118 4 5 5 1 1 11.2 4.5
Dyspnea 124 4 1 4 0 1 6.7 3.0
Interstitial pneumonia 124 4 1 4 0 1 6.7 3.0
Neuropathy 128 0 5 0 0 1 3.7 0.0
Rash 114 6 8 5 0 1 14.2 3.7
Edema 131 2 1 0 0 0 2.2 0.0
Mucositis 130 1 3 0 0 0 3.0 0.0
Allergic reaction 132 0 2 0 0 0 1.5 0.0
AST aspartate transaminase, ALT alanine aminotransferase
Table 6 Adverse events in patients treated as adjuvant/first-line setting (n = 32)
Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 3 3 8 10 7 1 87.5 53.1
Neutrophils 2 3 5 8 13 1 90.6 65.6
Hemoglobin 10 8 8 5 0 1 65.6 15.6
Platelets 19 3 6 3 0 1 37.5 9.4
AST 22 6 2 1 0 1 28.1 3.1
ALT 22 5 1 3 0 1 28.1 9.4
Anorexia 13 14 5 0 0 0 59.4 0.0
Nausea 17 11 4 0 0 0 46.9 0.0
Vomiting 26 5 1 0 0 0 18.8 0.0
Diarrhea 26 4 1 1 0 0 18.8 3.1
Fatigue 14 12 5 1 0 0 56.3 3.1
Febrile neutropenia 29 0 0 3 0 0 9.4 9.4
Fever 24 6 1 1 0 0 25.0 3.1
Infection 29 0 1 2 0 0 9.4 6.3
Dyspnea 31 0 0 1 0 0 3.1 3.1
Interstitial pneumonia 30 2 0 0 0 0 6.3 0.0
Neuropathy 32 0 0 0 0 0 0.0 0.0
Rash 24 4 3 1 0 0 25.0 3.1
Edema 30 2 0 0 0 0 6.3 0.0
Mucositis 31 0 1 0 0 0 3.1 0.0
Allergic reaction 32 0 0 0 0 0 0.0 0.0
AST aspartate transaminase, ALT alanine aminotransferase
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treated non-small cell lung cancer (NSCLC) over DOC
alone, was early terminated due to the unexpectedly high
incidence of interstitial pneumonia (grade 3 and 4 pneu-
monitis was observed in 12.3%) and three treatment-
related deaths (4.6%) in the GD arm [23]. The risk of
lung toxicities by GD could not be ignored especially in
Japan, since the unexpected severe pneumonitis in
JCOG0104 was observed in Japanese patients.
Since few interstitial pneumonia were described in the
past studies of GD for BSTS [11–16, 19–22], it has been
supposed that GD would be relatively safe regarding inter-
stitial pneumonia in the treatment of BSTS. In the present
study, interstitial pneumonia was observed 9 (6.7%) out of
134 patients for all grade and 4 (3.0%) for grade 3. All the
patients (five out of 134) with symptomatic pneumonia
(grade 2/3) were successfully treated by steroid-pulse
therapy, and no regimen-related death was observed. It
was noteworthy that all five patients were received prior
chemotherapy, and median number of previous regimens
was 3. Furthermore, three out of five patients had been
treated with radiotherapy. When GD was given as first-
line or adjuvant setting, symptomatic pneumonitis was
not observed. Although definite risk factors for interstitial
pneumonia caused by GD are still unknown, a careful
attention to lung toxicity should be paid even in the
treatment for BSTS, especially when the patient has been
treated with prior chemotherapy and/or radiotherapy.
The feasibility and efficacy of GD for BSTS have been
previously reported from the USA and Europe [11, 12,
16, 19–22]; however, those were not well analyzed in
Asian population, especially in Japan. Only a few small
studies of GD for BSTS were reported from Asian coun-
tries [13–15]. Furthermore, there was no description
about interstitial pneumonia or lung toxicities by GD in
these studies. Thus, the present study is the largest series
of GD for Asian patients with BSTS, and is reporting the
lung toxicities of GD in the treatment for BSTS in Asian
patients for the first time.
In addition to the less toxicity, GD regimen is also
thought to be as effective as DOX+IFO. In a randomized
phase II trial comparing perioperative chemotherapy
with GD and DOX+IFO for STS, 2-year PFS in the GD
arm and the DOX+IFO arm were 74 and 57%, respect-
ively [22]. The results suggested that GD is promising
for a phase III trial.
In the present study, the results demonstrated promis-
ing effects of GD especially as adjuvant or first-line setting
on survival of the patients with BSTS. Taken together, the
JCOG BSTTSG is now conducting a randomized phase
II/III study, JCOG1306, to elucidate the efficacy and safety
Table 7 Adverse events in patients treated as second-or-greater line setting (n = 102)
Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 6 5 13 34 42 2 92.2 74.5
Neutrophils 7 4 12 22 54 3 90.2 74.5
Hemoglobin 17 33 30 18 2 2 81.4 19.6
Platelets 36 18 12 21 13 2 62.7 33.3
AST 65 32 1 2 0 2 34.3 2.0
ALT 60 30 8 2 0 2 39.2 2.0
Anorexia 39 45 10 2 0 6 55.9 2.0
Nausea 48 38 10 1 0 5 48.0 1.0
Vomiting 77 17 3 0 0 5 19.6 0.0
Diarrhea 86 9 1 1 0 5 10.8 1.0
Fatigue 36 47 10 5 0 4 60.8 4.9
Febrile neutropenia 91 0 0 10 0 1 9.8 9.8
Fever 73 16 11 0 0 2 26.5 0.0
Infection 89 4 4 3 1 1 11.8 3.9
Dyspnea 93 4 1 3 0 1 7.8 2.9
Interstitial pneumonia 94 2 1 4 0 1 6.9 3.9
Neuropathy 96 0 5 0 0 1 4.9 0.0
Rash 90 2 5 4 0 1 10.8 3.9
Edema 101 0 1 0 0 0 1.0 0.0
Mucositis 99 1 2 0 0 0 2.9 0.0
Allergic reaction 100 0 2 0 0 0 2.0 0.0
AST aspartate transaminase, ALT alanine aminotransferase
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of perioperative chemotherapy by GD comparing with
DOX+IFO for operable high-grade STS [26].
It is noteworthy that the dose of GD and its efficacy
were not paralleled in the present study. RR and survival
in the patients treated with G900/D70 were better than
those with >G900/D70. One possible explanation of the
discrepancy was the influence of adverse effects caused by
GD. The incidences of adverse events in the patients
treated with >G900/D70 were more frequent than those
with G900/D70. For instance, neutropenia and decrease in
platelet were observed in 83.3 and 38.9% of the patients in
G900/D70 group, whereas those in >G900/D70 group
were 96.9 and 62.5%, respectively. Thus, it is possible that
the higher incidence of adverse events in >G900/D70
group might associate with the inferior outcome because
of discontinuation or dose reduction of GD. It has been
reported that approximately half of the patients were re-
quired dose reduction of GD because of adverse effects in
the previous randomized phase II trials using G900/D100
[18, 21]. Thus, such doses around G900/D100 might be
too high for the patients with BSTS.
Another possibility was the influence of previous treat-
ments. Since the number of chemotherapy-naïve pa-
tients was larger in G900/D70 group (50.0% of the
patients) than that in >G900/D70 group (31.3%), there is
a possibility that more drug-resistant tumors were in-
cluded in the latter group, which might lead to the lower
response to GD. In this regard, when the response to
GD was compared only for the chemotherapy-naïve
patients, RR and median OS were 0% (0/10) and
16.2 months in >G900/D70 group, whereas those were
33.3% (3/9) and 13.8 months comparably in G900/D70
group, respectively. These results suggest that G900/D70
might be useful for BSTS, especially in the treatment for
chemotherapy-naïve patients.
In summary, it is suggested that the incidences of the
severe adverse events including lung toxicities in the
patients without prior chemotherapy or radiotherapy
were lower than those with prior chemotherapy and/or
radiation. GD might be effective not only as second-line
therapy for advanced BSTS but also as adjuvant or first-
line chemotherapy for BSTS. Since GD can be adminis-
tered in an outpatient setting due to its lower toxicities,
GD is promising for further investigation by phase III
trials JCOG1306 for the patients with BSTS.
Conclusions
This is the first report demonstrating the precise profiles
of the adverse events of GD for the Japanese patients with
BSTS, and one of the largest series analyzing 134 patients
with BSTS treated by GD. GD used as both first- and sec-
ond/later line is effective chemotherapy for a proportion
of patients with advanced BSTS. Higher response rate and
better outcome were achieved in chemotherapy-naïve pa-
tients. This regimen is associated with high incidence of
severe hematological toxicity, as well as the risk of severe
pneumonitis, especially in pre-treated patients.
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